Albrecht Schwab
Research Subjects
Research Interests
Albrecht Schwab has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Oeckinghaus
Institute of Molecular Tumor Biology, University of Münster, Münster, Germany
1 shared publication - Benedikt Fels
Institute of Physiology, University of Luebeck, 23562 Luebeck, Germany
1 shared publication - Eva Wardelmann
Gerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany
1 shared publication - Ilka Neumann
Institute of Physiology II and
1 shared publication - Karolina Najder
Institute of Physiology II, University Hospital Münster, Münster, Germany
1 shared publication - Klavs Grantins
Gerhard-Domagk-Institute of Pathology, University of Münster, Münster, Germany
1 shared publication
Latest Publications
- Open Access
- 9 October 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (19)
Acid-base homeostasis orchestrated by NHE1 defines the pancreatic stellate cell phenotype in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) progresses in an organ with a unique pH landscape, where the stroma acidifies after each meal. We hypothesized that disrupting this pH landscape during PDAC progression triggers pancreatic stellate cells (PSCs) and cancer-associated fibroblasts (CAFs) to induce PDAC fibrosis. We revealed that alkaline environmental pH was sufficient to induce PSC differentiation to a myofibroblastic phenotype. We then mechanistically dissected this finding, focusing on the involvement of the Na + /H + exchanger NHE1. Perturbing cellular pH homeostasis by inhibiting NHE1 with cariporide partially altered the myofibroblastic PSC phenotype. To show the relevance of this finding in vivo, we targeted NHE1 in murine PDAC (KPfC). Indeed, tumor fibrosis decreased when mice received the NHE1-inhibitor cariporide in addition to gemcitabine treatment. Moreover, the tumor immune infiltrate shifted from granulocyte rich to more lymphocytic. Taken together, our study provides mechanistic evidence on how the pancreatic pH landscape shapes pancreatic cancer through tuning PSC differentiation.
- 9 October 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (19)
Open AccessAcid-base homeostasis orchestrated by NHE1 defines the pancreatic stellate cell phenotype in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) progresses in an organ with a unique pH landscape, where the stroma acidifies after each meal. We hypothesized that disrupting this pH landscape during PDAC progression triggers pancreatic stellate cells (PSCs) and cancer-associated fibroblasts (CAFs) to induce PDAC fibrosis. We revealed that alkaline environmental pH was sufficient to induce PSC differentiation to a myofibroblastic phenotype. We then mechanistically dissected this finding, focusing on the involvement of the Na + /H + exchanger NHE1. Perturbing cellular pH homeostasis by inhibiting NHE1 with cariporide partially altered the myofibroblastic PSC phenotype. To show the relevance of this finding in vivo, we targeted NHE1 in murine PDAC (KPfC). Indeed, tumor fibrosis decreased when mice received the NHE1-inhibitor cariporide in addition to gemcitabine treatment. Moreover, the tumor immune infiltrate shifted from granulocyte rich to more lymphocytic. Taken together, our study provides mechanistic evidence on how the pancreatic pH landscape shapes pancreatic cancer through tuning PSC differentiation.